These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11078469)

  • 21. A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.
    Mikhailova EA; Ashcroft SJ; Mikhailov MV
    Anal Biochem; 2002 Aug; 307(2):383-5. PubMed ID: 12202259
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sulfonylurea receptors and their interaction with glimepiride].
    Zueva NA; Sologub NV; Efimov AS
    Lik Sprava; 2003; (2):35-9. PubMed ID: 12774471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
    Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
    Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mitiglinide (KAD-1229)].
    Kusama H; Shibata N
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():559-65. PubMed ID: 12387051
    [No Abstract]   [Full Text] [Related]  

  • 25. Gliclazide modified release.
    Rambiritch V; Naidoo P
    Drugs; 2005; 65(10):1449-50. PubMed ID: 15977973
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients.
    Czyrski A; Resztak M; Hermann T
    Biomed Pharmacother; 2018 Oct; 106():1267-1270. PubMed ID: 30119196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.
    Sperling MA
    N Engl J Med; 2006 Aug; 355(5):507-10. PubMed ID: 16885555
    [No Abstract]   [Full Text] [Related]  

  • 29. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating diabetes today: a matter of selectivity of sulphonylureas.
    Seino S; Takahashi H; Takahashi T; Shibasaki T
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfonylurea stimulation of insulin secretion.
    Proks P; Reimann F; Green N; Gribble F; Ashcroft F
    Diabetes; 2002 Dec; 51 Suppl 3():S368-76. PubMed ID: 12475777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.
    Aguilar-Bryan L; Nichols CG; Wechsler SW; Clement JP; Boyd AE; González G; Herrera-Sosa H; Nguy K; Bryan J; Nelson DA
    Science; 1995 Apr; 268(5209):423-6. PubMed ID: 7716547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
    Matthews DR; Boland O
    Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The sulfonylurea receptor].
    Inagaki N; Gonoi T; Seino S
    Seikagaku; 1997 Sep; 69(9):1067-80. PubMed ID: 9364874
    [No Abstract]   [Full Text] [Related]  

  • 36. KATP channel openers: structure-activity relationships and therapeutic potential.
    Mannhold R
    Med Res Rev; 2004 Mar; 24(2):213-66. PubMed ID: 14705169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new mesangial triumvirate: sulfonylureas, their receptors and endosulfines.
    Yee J; Szamosfalvi B
    Exp Nephrol; 2002; 10(1):1-6. PubMed ID: 11803199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenosine triphosphate-sensitive potassium (K(ATP)) channel activity is coupled with insulin resistance in obesity and type 2 diabetes mellitus.
    Wasada T
    Intern Med; 2002 Feb; 41(2):84-90. PubMed ID: 11868613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.